Jim Simons Verona Pharma PLC Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 31,044 shares of VRNA stock, worth $892,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,044

Holding current value

$892,825

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$11.48 - $17.02 $356,385 - $528,368	31,044 New	31,044 $448,000
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $753,066 - $2.47 Million	181,900 Added 645.04%	210,100 $2.15 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $5.06 $100,110 - $142,692	28,200 New	28,200 $118,000
Q1 2021 May 13, 2021	SELL	$7.08 - $9.33 $175,584 - $231,384	-24,800 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$5.51 - $8.11 $136,648 - $201,128	24,800 New	24,800 $174,000
Q3 2020 Nov 13, 2020	SELL	$4.45 - $10.2 $95,274 - $218,381	-21,410 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.6 - $6.12 $77,076 - $131,029	21,410 New	21,410 $100,000
Q1 2020 May 14, 2020	SELL	$2.16 - $7.28 $27,000 - $91,000	-12,500 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.7 - $6.58 $46,250 - $82,250	12,500 New	12,500 $72,000
Q3 2019 Nov 13, 2019	SELL	$4.03 - $5.44 $41,509 - $56,032	-10,300 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$5.1 - $6.91 $7,139 - $9,674	-1,400 Reduced 11.97%	10,300 $53,000
Q1 2019 May 14, 2019	BUY	$5.52 - $10.0 $64,583 - $117,000	11,700 New	11,700 $76,000

Others Institutions Holding VRNA

# of Institutions

137

Shares Held

66.7M

Call Options Held

495K

Put Options Held

486K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $1.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account